This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Date and time:

30.07.24 at 12:30-13:45 EDT



Welcome and introductions

Neuroinflammation: insights into the potential mechanisms underlying neurodegeneration in Alzheimer’s disease

Unlocking the potential of biomarkers for Alzheimer's disease

Exploring the next generation of potential therapies for Alzheimer’s disease

Fireside chat. Breakthroughs in Alzheimer’s disease: implications for people with Alzheimer’s disease, care partners, and beyond

Q&A (Alzheimer’s disease: driving change in early disease intervention)

Summary and close


Marwan Sabbagh

Barrow Neurological Institute, Phoenix, USA

Dr Marwan Noel Sabbagh is a board-certified neurologist and geriatric neurologist; he has dedicated his career to finding a cure for Alzheimer’s and other age-related neurodegenerative diseases.


Dr Sabbagh is a leading investigator for many prominent national Alzheimer’s treatment trials. He is on the editorial board for the Journal of Alzheimer's Disease and Alzheimer’s and Dementia TRCI, and Editor-in-Chief of Neurology and Therapy. He has authored and co-authored over 430 medical and scientific articles on Alzheimer’s research. 


Dr Sabbagh is the author of The Alzheimer’s Answer: Reduce Your Risk and Keep Your Brain Healthy, and The Alzheimer’s Prevention Cookbook: 100 Recipes to Boost Brain Health. He has edited Palliative Care for Advanced Alzheimer’s and Dementia: Guidelines and Standards for Evidence-Based Care and Geriatric Neurology, published in 2014, Fighting for my Life: living in the shadow of Alzheimer’s disease in 2019, and Strong Heart, Sharp Mind published in 2022.


Dr Sabbagh earned his undergraduate degree from the University of California, Berkeley, USA, and his medical degree from the University of Arizona in Tucson. He completed his residency training in neurology at Baylor College of Medicine, Houston, TX, and his fellowship in geriatric neurology and dementia at the University of California, San Diego School of Medicine, where he served on the faculty as an assistant professor. Before joining the faculty of the Barrow Neurological Institute in Phoenix, AZ, he was the Camille and Larry Ruvo Chair for Brain Health, the Director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, NV, and the founding principal investigator of the National Institute on Aging-funded Alzheimer’s Disease Research Center in NV. From 2000 to 2015, Dr Sabbagh was the director of the Banner Sun Health Research Institute in Sun City, AZ. From 2015 to 2018, he was the Karsten Solheim Chair for Alzheimer’s research at the Barrow Neurological Institute. Presently, in addition to being Vice Chair, Dr Sabbagh also serves as Associate Program Director for Research for the Neurology Residency at Barrow Neurological Institute.

Read full bio

Charlotte Teunissen

Amsterdam University Medical Center, Amsterdam, Netherlands

Charlotte Teunissen is a full professor in neurochemistry at the Amsterdam University Medical Center in the Netherlands. Her aim is to improve care for patients with neurological diseases by utilizing body fluid biomarkers for diagnosis, stratification, prognosis, and monitoring of treatment responses. Studies conducted by Professor Teunissen’s research group span the entire spectrum of biomarker development, from biomarker identification (using omics methods), followed by assay development, analytical and clinical validation, and lastly implementation in clinical practice and trials.


Professor Teunissen’s young and dynamic lab has extensive expertise with state-of-the-art technologies, such as various ultrasensitive and antibody-based assays, and vitro diagnostics for clinical routine lab analysis. She is responsible for the large biobank at the Amsterdam Dementia Cohort, which contains >10,000 paired cerebrospinal fluid (CSF) and plasma/serum samples of individuals who have visited the memory clinic of the Alzheimer Center Amsterdam.


Professor Teunissen leads several collaborative international biomarker networks, such as the Society for Neurochemistry and routine CSF analysis and the Alzheimer Association-Global Biomarker Standardization and Blood Based Biomarkers and the Body fluid Biomarkers PIA, and the recently founded CORAL consortium (Community using Olink for Research on Alzheimer’s Disease and other neurological diseases). She is the coordinator of the Marie Curie MIRIADE (Multi‐omics Interdisciplinary Research Integration to Address DEmentia diagnosis) project, aiming to train 15 novel researchers into innovative strategies to develop dementia biomarkers; as well as the EU Joint Programme – Neurodegenerative Disease Research bPRIDE (blood Proteins for early Discrimination of dEmentias) project, which aims to develop blood-based biomarkers for early differential diagnoses of specific dementias. 

Read full bio